Finance

Beta
Lists
FRX:TSE
Fennec Pharmaceuticals Inc
CA$12.72
0.00%
(0.00) 1D
Jun 3, 11:42:37 AM GMT-4  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for FRX...
Mkt. cap
421.07M
Avg. vol.
1.55K
Volume
12.00
52-wk high
CA$14.24
52-wk low
CA$7.59
EPS
-CA$0.40
Beta
0.83
Shares outstanding
34.74M
No. of employees
35
Mkt. cap
421.07M
Avg. vol.
1.55K
Volume
12.00
52-wk high
CA$14.24
52-wk low
CA$7.59
EPS
-CA$0.40
Beta
0.83
Shares outstanding
34.74M
No. of employees
35
News stories
From sources across the web
About Fennec Pharmaceuticals Inc
CEO-
Employees35
Founded1996
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitefennecpharma.com
Last report
May 14, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
- / -
Revenue / Est. (USD)
15.11M / 14.40M
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
9.65M
12.46M
13.78M
15.11M
Cost of goods sold
967.00K
660.00K
1.76M
570.00K
Cost of revenue
967.00K
660.00K
1.76M
570.00K
Research and development expenses
107.00K
29.00K
20.00K
49.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.31M
11.96M
14.55M
14.61M
Operating expense
11.42M
11.99M
14.57M
14.66M
Total operating expenses
12.38M
12.65M
16.33M
15.23M
Operating income
-2.73M
-189.00K
-2.55M
-119.00K
Other non operating income
-
-
-
-
EBT including unusual items
-3.15M
-638.00K
-4.68M
201.00K
EBT excluding unusual items
-3.15M
-638.00K
-2.66M
201.00K
Income tax expense
-
-
106.00K
-
Effective tax rate
-
-
-2.26%
-
Other operating expenses
-
-
-
-
Net income
-3.15M
-638.00K
-4.79M
201.00K
Net profit margin
-32.66%
-5.12%
-34.75%
1.33%
Earnings per share
-0.11
-0.02
-0.10
-
Interest and investment income
171.00K
152.00K
228.00K
339.00K
Interest expense
-607.00K
-598.00K
-334.00K
-7.00K
Net interest expenses
-436.00K
-446.00K
-106.00K
332.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.71M
-163.00K
-2.53M
-93.00K
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer